Aruga Atsushi
Institute of Advanced Biomedical Engineering and Science, Tokyo Women's Medical University.
Nihon Rinsho. 2010 Jun;68(6):1107-10.
Dendritic cell is the most effective antigen presenting cells in human. We performed a couple of dendritic cell-based cancer immunotherapy in Tokyo Women's Medical University. Autologous tumor lysates or synthetic peptides are pulsed with dendritic cells to make the dendritic cell vaccine. Tumor-pulsed dendritic cell vaccine (TP-DC) or peptide pulsed dendritic cell vaccine (PP-DC) are safe and useful in the patients with advanced cancer. Antigen unpulsed immature dendritic cell could work at a cancer vaccine when they inject into tumors in vivo. Dendritic cell-activated T cells (DCAT) in vitro are also useful tools for cancer treatment. In order to obtain a good evidence of dendritic cell-based immunotherapy, we need to perform the randomized trial near the future.
树突状细胞是人体中最有效的抗原呈递细胞。我们在东京女子医科大学进行了多项基于树突状细胞的癌症免疫治疗。用自体肿瘤裂解物或合成肽脉冲处理树突状细胞以制备树突状细胞疫苗。肿瘤脉冲树突状细胞疫苗（TP-DC）或肽脉冲树突状细胞疫苗（PP-DC）对晚期癌症患者是安全且有用的。未脉冲抗原的未成熟树突状细胞在体内注射到肿瘤中时可作为癌症疫苗发挥作用。体外树突状细胞激活的T细胞（DCAT）也是癌症治疗的有用工具。为了获得基于树突状细胞的免疫治疗的确凿证据，我们需要在不久的将来进行随机试验。
